Justin R. Nickell
Role not yet determined Is this you? Add your title
Also affiliated: University of Kentucky (2004–2024); Albert B. Chandler Hospital (2004–2006); Markey Cancer Center (2014); University of Florida (2019)
Research Areas
Biomedical Subjects
Biography and Research Information
OverviewAI-generated summary
Justin R. Nickell's research focuses on the neuropharmacological effects of substances, particularly in relation to vesicular monoamine transporter-2 (VMAT2) inhibition. His work investigates how VMAT2 inhibitors can mitigate the toxic effects of stimulants like methamphetamine on dopamine systems. A recent publication demonstrates that the VMAT2 inhibitor JPC-141 effectively prevents methamphetamine-induced dopamine toxicity and blocks methamphetamine self-administration in rat models. Nickell's scholarship includes 33 publications with 639 citations and an h-index of 14. He has collaborated with researchers including Peter A. Crooks, Cassie M. Chandler, John P. Culver, and A. George Wilson at the University of Arkansas for Medical Sciences.
Metrics
- h-index: 14
- Publications: 33
- Citations: 653
Selected Publications
-
Vesicular monoamine transporter-2 inhibitor JPC-141 prevents methamphetamine-induced dopamine toxicity and blocks methamphetamine self-administration in rats (2024)
-
GZ-11608, a Vesicular Monoamine Transporter-2 Inhibitor, Decreases the Neurochemical and Behavioral Effects of Methamphetamine (2019)
Collaboration Network
Top Collaborators
- GZ-11608, a Vesicular Monoamine Transporter-2 Inhibitor, Decreases the Neurochemical and Behavioral Effects of Methamphetamine
- Vesicular monoamine transporter-2 inhibitor JPC-141 prevents methamphetamine-induced dopamine toxicity and blocks methamphetamine self-administration in rats
- GZ-11608, a Vesicular Monoamine Transporter-2 Inhibitor, Decreases the Neurochemical and Behavioral Effects of Methamphetamine
- Vesicular monoamine transporter-2 inhibitor JPC-141 prevents methamphetamine-induced dopamine toxicity and blocks methamphetamine self-administration in rats
- GZ-11608, a Vesicular Monoamine Transporter-2 Inhibitor, Decreases the Neurochemical and Behavioral Effects of Methamphetamine
- Vesicular monoamine transporter-2 inhibitor JPC-141 prevents methamphetamine-induced dopamine toxicity and blocks methamphetamine self-administration in rats
- GZ-11608, a Vesicular Monoamine Transporter-2 Inhibitor, Decreases the Neurochemical and Behavioral Effects of Methamphetamine
- GZ-11608, a Vesicular Monoamine Transporter-2 Inhibitor, Decreases the Neurochemical and Behavioral Effects of Methamphetamine
- GZ-11608, a Vesicular Monoamine Transporter-2 Inhibitor, Decreases the Neurochemical and Behavioral Effects of Methamphetamine
- GZ-11608, a Vesicular Monoamine Transporter-2 Inhibitor, Decreases the Neurochemical and Behavioral Effects of Methamphetamine
- Vesicular monoamine transporter-2 inhibitor JPC-141 prevents methamphetamine-induced dopamine toxicity and blocks methamphetamine self-administration in rats
- Vesicular monoamine transporter-2 inhibitor JPC-141 prevents methamphetamine-induced dopamine toxicity and blocks methamphetamine self-administration in rats
- Vesicular monoamine transporter-2 inhibitor JPC-141 prevents methamphetamine-induced dopamine toxicity and blocks methamphetamine self-administration in rats
Similar Researchers
Based on overlapping research topics